The new drug application transfer process for Iopidine 1%, Maxitrol 0.1% and Moxeza 0.5% is complete, Harrow Health announced in a press release. Harrow acquired the commercialization rights to the ophthalmic drops from Novartis in 2021.
In addition, Iopidine 1% (apraclonidine hydrochloride) and Maxitrol (neomycin, polymyxin B sulfate and dexamethasone) are now commercially available and can be ordered through Cardinal’s Cordlogistics, Harrow’s customer service ordering partner.
“We are pleased to have completed the transfer of the NDAs for these workhorse products, allowing